Organon, a leading women's healthcare organisation, has announced the completion of a licensing deal for Miudella, a hormone-free intrauterine device (IUD). This development marks a significant milestone for menstrual health in the UK, providing women with a more convenient and effective alternative for contraception.
According to a statement from Organon, Miudella has been licensed from Swedish company Ixcela, a specialist in reproductive health solutions. The device is designed to offer a hormone-free alternative for women seeking long-term contraception, providing a more convenient option for those who may experience side effects from hormone-based contraceptives.
While the exact cost of Miudella is yet to be confirmed, Organon has stated that it will be priced competitively with existing IUDs in the UK market. This news is set to benefit women seeking a more convenient and effective form of contraception, as well as those who may experience side effects from hormone-based options.
Under UK law, women are entitled to free or low-cost contraception, regardless of their age or income. This includes access to IUDs, which are typically available on the NHS for women under 19 and those who are pregnant or breastfeeding.
The licensing deal for Miudella is expected to be available to UK customers in the coming months. Women interested in learning more about Miudella and its availability can visit the Organon website for updates.